$12.5 million in gross financings raised during the quarter, with an additional $9 million raised by Citius Oncology in July 2025 , to facilitate LYMPHIR pre-launch initiatives and drive successful market introduction

CRANFORD, N.J. , Aug. 12, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today reported financial results for its fiscal third quarter ended June 30, 2025 , and provided a business update.

"During the third quarter, Citius advanced its strategic priorities, and we believe we are now operationally positioned to transition from a development-stage enterprise to a fully integrated commercial or

See Full Page